Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland.

Hdl Handle:
http://hdl.handle.net/10147/207982
Title:
Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland.
Affiliation:
Dermatological Sciences, Salford Royal Hospital, The University of Manchester,, Manchester Academic Health Science Centre, Manchester M6 8HD, U.K. Department of , Dermatology, Royal Devon & Exeter Hospital, Exeter, U.K. Department of, Dermatology, Royal Liverpool and Broadgreen NHS Trust, Liverpool, U.K. St John's , Institute of Dermatology, King's College London and Guy's and St Thomas' NHS, Foundation Trust, London, U.K. Department of Dermatology, Queen's Medical Centre,, Nottingham, U.K. St Vincent's University Hospital, Dublin, Ireland Department of , Dermatology, Waterford Regional Hospital Ardkeen, Waterford, Ireland Department, of Dermatology, Western Infirmary, Glasgow, U.K. Department of Dermatology, The, Royal Free Hospital, London, U.K. Department of Dermatology, Royal Gwent, Hospital, Newport, U.K.
Citation:
Br J Dermatol. 2012 Jan;166(1):189-195. doi: 10.1111/j.1365-2133.2011.10638.x.
Journal:
The British journal of dermatology
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207982
DOI:
10.1111/j.1365-2133.2011.10638.x
PubMed ID:
21929536
Abstract:
Background There are limited data on the use of ustekinumab outside of clinical trials. Objectives To assess the efficacy and safety of ustekinumab in patients with severe psoriasis attending 10 dermatology centres in the U.K. and Ireland. Methods A retrospective case-note review of 129 patients with psoriasis treated with ustekinumab. Results Baseline Psoriasis Area and Severity Index (PASI) was 22.9 +/- 10.1 (mean +/- SD). After 16 weeks of treatment with ustekinumab PASI 75 (75% reduction in PASI) was observed in 63.0% (n = 80/127) of patients, although four patients required concomitant therapy at the 16-week time point. Previous biologic use did show a small, non-significant trend towards treatment failure. A PASI 75 response was seen in 29.4% (n = 5/17) of individuals weighing 90-100 kg and treated with the standard 45 mg ustekinumab dose compared with PASI 75 of 70.3%, 71.4%, 75.0% and 55.6% for weight groups < 80, 80-90, 100-110 and > 110 kg, respectively (P = 0.024). Ustekinumab therapy was well tolerated; serious adverse events were observed in 2.3% (n = 3/129) of patients. Conclusions Ustekinumab is a novel biologic agent for psoriasis. When used in everyday clinical practice it demonstrates high levels of short-term therapeutic efficacy with an acceptable short-term safety profile.
Language:
ENG
ISSN:
1365-2133 (Electronic); 0007-0963 (Linking)

Full metadata record

DC FieldValue Language
dc.date.accessioned2012-02-01T10:53:13Z-
dc.date.available2012-02-01T10:53:13Z-
dc.date.issued2012-02-01T10:53:13Z-
dc.identifier.citationBr J Dermatol. 2012 Jan;166(1):189-195. doi: 10.1111/j.1365-2133.2011.10638.x.en_GB
dc.identifier.issn1365-2133 (Electronic)en_GB
dc.identifier.issn0007-0963 (Linking)en_GB
dc.identifier.pmid21929536en_GB
dc.identifier.doi10.1111/j.1365-2133.2011.10638.xen_GB
dc.identifier.urihttp://hdl.handle.net/10147/207982-
dc.description.abstractBackground There are limited data on the use of ustekinumab outside of clinical trials. Objectives To assess the efficacy and safety of ustekinumab in patients with severe psoriasis attending 10 dermatology centres in the U.K. and Ireland. Methods A retrospective case-note review of 129 patients with psoriasis treated with ustekinumab. Results Baseline Psoriasis Area and Severity Index (PASI) was 22.9 +/- 10.1 (mean +/- SD). After 16 weeks of treatment with ustekinumab PASI 75 (75% reduction in PASI) was observed in 63.0% (n = 80/127) of patients, although four patients required concomitant therapy at the 16-week time point. Previous biologic use did show a small, non-significant trend towards treatment failure. A PASI 75 response was seen in 29.4% (n = 5/17) of individuals weighing 90-100 kg and treated with the standard 45 mg ustekinumab dose compared with PASI 75 of 70.3%, 71.4%, 75.0% and 55.6% for weight groups < 80, 80-90, 100-110 and > 110 kg, respectively (P = 0.024). Ustekinumab therapy was well tolerated; serious adverse events were observed in 2.3% (n = 3/129) of patients. Conclusions Ustekinumab is a novel biologic agent for psoriasis. When used in everyday clinical practice it demonstrates high levels of short-term therapeutic efficacy with an acceptable short-term safety profile.en_GB
dc.language.isoENGen_GB
dc.titlePractical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland.en_GB
dc.contributor.departmentDermatological Sciences, Salford Royal Hospital, The University of Manchester,, Manchester Academic Health Science Centre, Manchester M6 8HD, U.K. Department of , Dermatology, Royal Devon & Exeter Hospital, Exeter, U.K. Department of, Dermatology, Royal Liverpool and Broadgreen NHS Trust, Liverpool, U.K. St John's , Institute of Dermatology, King's College London and Guy's and St Thomas' NHS, Foundation Trust, London, U.K. Department of Dermatology, Queen's Medical Centre,, Nottingham, U.K. St Vincent's University Hospital, Dublin, Ireland Department of , Dermatology, Waterford Regional Hospital Ardkeen, Waterford, Ireland Department, of Dermatology, Western Infirmary, Glasgow, U.K. Department of Dermatology, The, Royal Free Hospital, London, U.K. Department of Dermatology, Royal Gwent, Hospital, Newport, U.K.en_GB
dc.identifier.journalThe British journal of dermatologyen_GB
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.